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Abstract
Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic 
autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-
phase clinical trials in both industry and academic sponsored studies. There is a broad consensus 
that despite different tissue sourcing and varied culture expansion protocols, human MSC-like cell 
products likely share fundamental mechanisms of action mediating their anti-inflammatory and 
tissue repair functionalities. Identification of functional markers of potency and reduction to 
practice of standardized, easily deployable methods of measurements of such would benefit the 
field. This would satisfy both mechanistic research as well as development of release potency 
assays to meet Regulatory Authority requirements for conduct of advanced clinical studies and 
their eventual registration. In response to this unmet need, the International Society for Cellular 
Therapy (ISCT) addressed the issue at an international workshop in May 2015 as part of the 21st 
ISCT annual meeting in Las Vegas. The scope of the workshop was focused on discussing 
potency assays germane to immunomodulation by MSC-like products in clinical indications 
targeting immune disorders. We here provide consensus perspective arising from this forum. We 
propose that focused analysis of selected MSC markers robustly deployed by in vitro licensing and 
metricized with a matrix of assays should be responsive to requirements from Regulatory 
Authorities. Workshop participants identified three preferred analytic methods that could inform a 
matrix assay approach: quantitative RNA analysis of selected gene products; flow cytometry 
analysis of functionally relevant surface markers and protein-based assay of secretome. We also 
advocate that potency assays acceptable to the Regulatory Authorities be rendered publicly 
accessible in an “open-access” manner, such as through publication or database collection.
Keywords
Mesenchymal Stromal cells; potency assays; release assays; matrix assays; immune functional 
testing; clinical trials; ISCT
Culture-expanded mesenchymal stromal cells (MSCs) meeting minimal core identity for 
MSCs as defined by International Society for Cellular Therapy (ISCT) in 2006 [1] derived 
from marrow, adipose tissue, umbilical cord tissue and other sources from either autologous 
or allogeneic donor sources are being studied in clinical trials across numerous regulatory 
jurisdictions worldwide. The ailments targeted with this cell pharmaceutical platform fall 
roughly within two pathophysiological categories: immune/inflammatory and tissue repair/
restoration [2]. It is now widely accepted that the pharmaceutical effect of MSC-like cells is 
predominantly mediated by paracrine and contact factors arising from intrinsic MSC 
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physiological processes that are maintained after culture expansion. It is further accepted 
that following in vivo delivery, MSCs are further responsive to environmental cues 
encountered in situ leading to additional cellular functionalities [3]. Culture expanded MSC-
like cells are unambiguously classified as a more-than-minimal-manipulated cellular and 
gene therapy (CGT) product regulated in the United States under section 351 of the Public 
Health Service Act (PHS Act) (42 U.S.C. 262). As a type of CGT product, MSC-like cells 
require an Investigational New Drug Application (IND) from the Food & Drug 
Administration (FDA) for conduct of clinical trials in the USA. The FDA further requires 
development of tests to measure potency as part of release criteria of advanced clinical trials 
designed to support marketing approval and registration. Similar requirements are made by 
the European Medicines Agency (EMA) for Advanced Therapy Medicinal Products 
(ATMPs), which include cell therapies, as defined by the European Regulation (European 
Commission [EC]) No. 1394 / 2007,1 further strengthened on December 30, 2008, and 
directly enclosed in the legislation of each EU member nation with no need of other 
implementation. The EU Regulation is in compliance with the 2004/23/EC directive on 
donation, supply and testing of human cells and tissues and with directive 2002/98/EC on 
human blood and blood components.2 The tripartite components of release criteria for MSC-
like cellular products in early phase clinical trials—identity, viability and sterility—raise 
little practical controversy and the consensus on markers for identity of MSC-like cells, 
considering their intrinsic heterogeneity and phenotype plasticity, is also reasonably well 
defined [1,4]. However, the issue of potency testing remains largely open-ended and is 
informed by the putative mechanism of action (MOA) of MSC-like cells in a given 
indication. Care must be made in distinguishing curiosity-driven research as part of ancillary 
studies on cell products and release potency assays required to satisfy the Regulatory 
Authorities. Although pre-clinical MOA studies will necessarily inform the methods and 
reduction to practice of deployable potency assays, the latter have specific requirements for 
the following as part of assay validation: accuracy, precision, specificity, linearity and range, 
system suitability, and robustness.
International regulatory authority guidance on potency tests for cellular 
therapy products
The FDA has published guidance with recommendations for developing tests to measure 
potency for CGT products.3 These recommendations are intended to clarify the potency 
information that could support an IND or a Biologics License Application. Because potency 
measurements are designed specifically for a particular product, their guidance does not 
make recommendations regarding specific types of potency assays nor does it propose 
acceptance criteria for product release. FDA guidance defines potency (strength is also 
synonymously used) as the therapeutic activity of the drug product as indicated by 
appropriate laboratory tests or by adequately developed and controlled clinical data. 
Regulatory Authorities are not prescriptive in what constitutes a definitive potency assay, 
1http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:EN:PDF.
2http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030:0040:EN:PDF.
3http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/
CellularandGeneTherapy/UCM243392.pdf.
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and FDA regulations allow for considerable flexibility in determining the appropriate 
measurements of potency for each product. Potency is determined on the basis of individual 
product attributes; therefore, the adequacy of potency tests is evaluated on a case-by-case 
basis. The Regulatory Authorities also recognizes the inherent challenges in defining 
potency assays (Table I). Similar guidance has been published by EMA, which defines 
potency as the quantitative measure of biological activity based on the attribute of the 
product, which is linked to the relevant biological properties. Consequently, the assay 
demonstrating the biological activity should be based on the intended biological effect, 
which should ideally be related to the clinical response and aimed at investigating major 
cellular functions by using surrogate markers and appropriate technology.4 The newly 
released guidelines of quality control of stem cell products by the Chinese National Health 
and Family Planning Commission5 mainly emphasized guidance for facility requirements, 
biological contaminants, viability and product consistency. No specific criterion was given 
on the issue of potency assay, and the guidance limits its recommendation to assessment of 
potency according to disease indications.
There is no single test that can adequately measure product attributes that predict clinical 
efficacy. Taking into consideration this limitation, the potency assay should represent the 
product’s mechanism of action (i.e., relevant therapeutic activity or intended biological 
effect). However, many CGT products, including MSC-like cells, have complex (e.g., rely 
on multiple biological activities) and/or not fully characterized mechanisms of action, 
making it difficult to determine which product attributes are most relevant to measuring 
potency. Indeed, it will be extraordinarily challenging to perform reductionist mechanistic 
experiments in human subjects that will conclusively define substantive MOA of MSC-like 
cells in vivo and meet modern standards of ethical conduct in clinical trials. Nonetheless, all 
attempts should be made to develop potency measurements that reflect the product’s 
relevant biological properties and that can also serve as a measure of comparability between 
production lots [5].Therefore, defining hypothesis-driven MOA based on correlative in vitro 
experiments and buttressed, where feasible, with comparative biology approach in animal 
systems will inform the choice of potency assays to be developed. The Regulatory 
Authorities anticipate that Manufacturers demonstrate clinical effectiveness by correlative 
“substantial evidence,” that is, evidence that the product will have the effect it purports or is 
represented to have under the conditions of use prescribed, recommended, or suggested in 
the labeling or proposed labeling thereof (section 505(d) of the FDC Act). The traditional 
approach for assessing the potency of biological products is to develop a quantitative 
biological assay (bioassay) that measures the activity of the product related to its specific 
ability to affect a given result and that also meets the criteria required by Regulatory 
Authorities (Table II).
Analytical methods to measure potency
Bioassays can provide a measure of potency by evaluating a product’s active ingredients 
within a living biological system. Bioassays can include in vivo animal studies, in vitro 
4http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/05/WC500187352.pdf.
5http://www.nhfpc.gov.cn/qjjys/s3581/201508/15d0dcf66b734f338c31f67477136cef.shtml.
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organ, tissue or cell culture systems, or any combination of these. Development of a 
quantitative bioassay for MSC-like products may be complicated by properties of the 
product and/or technical limitations of certain assays (see Table I). In cases in which 
development of a suitable bioassay is not feasible, it may be necessary to identify a 
surrogate measurement of biological activity. For example, the use of non-biological 
analytical assays performed outside of a living system that is practical and demonstrates 
adequate performance characteristics for lot release. Examples of such analytical assays 
provided by the FDA include methods that measure immunochemical (e.g., quantitative 
flow cytometry, enzyme-linked immunosorbent assay), molecular (e.g., reverse transcription 
polymerase chain reaction, quantitative polymerase chain reaction, microarray) or 
biochemical (e.g., protein binding, enzymatic reactions) properties of the product outside of 
a living system. Analytical assays can provide extensive product characterization data by 
evaluating immunochemical, biochemical and/or molecular attributes of the product. These 
attributes may be used to demonstrate potency if the surrogate measurement(s) can be 
substantiated by correlation to a relevant product-specific biological activity(s).
Assay matrix
The FDA states that a single biological or analytical assay may not provide an adequate 
measure of potency. The following are some potential reasons: (i) product has complex 
and/or not fully characterized mechanism of action, (ii) product has multiple active 
ingredients and/or multiple biological activities, (iii) limited product stability, or (iv) 
biological assay is not quantitative, not sufficiently robust or lacks precision. If one assay is 
not sufficient to measure the product attributes that indicates potency, then an alternative 
approach could be used, such as developing multiple complementary assays that measure 
different product attributes associated with quality, consistency and stability. When used 
together and when results are correlated with a relevant biological activity, these 
complementary assays should provide an adequate measure of potency. Such a collection of 
assays (referred to as an assay matrix) might consist of a combination of biological assays, 
biological and analytical assays or analytical assays alone. The assay matrix may include 
assays that give a quantitative readout (e.g., units of activity) and/or qualitative readout (e.g., 
pass–fail). If qualitative assays are used as part of an assay matrix to determine potency for 
lot release, stability or comparability studies, they should be accompanied by one or more 
quantitative assays. A concrete example of an assay matrix for MSC-like cells recognized by 
the FDA is detailed in a published report by Athersys Inc. (Cleveland, OH) outlining their 
effort in establishing an angiogenic potency assay for their MultiStem product based on 
measure of CXCL5, interleukin (IL)-8 and vascular endothelial growth factor (VEGF) 
production coupled to an in vitro cell-based angiogenic assay [6]. The correlative 
relationship between the surrogate measurement and biological activity may be established 
using various approaches, including comparison to preclinical/proof of concept data, in vivo 
data (animal or clinical) or in vitro cellular or biochemical data. The suitability of data used 
to support the correlative relationship between the surrogate assay and the biological activity 
of a MSC-like product will be evaluated on a case-by-case basis by the Regulatory 
Authorities and depends on or is influenced by the following: (i) type and relevance of the 
correlations being made, (ii) the amount of product information accumulated, (iii) how well 
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the biological activity of the product is understood, and (iv) how well the surrogate 
measurements reflects biological activity.
Defining release potency assays for MSC-like cells developed for 
immunomodulation
The open-ended guidance from the Regulatory Authorities and the published precedent of a 
matrix potency release assay approach used by Athersys Inc. for Multistem in support of 
their advanced clinical studies informs a path forward on how to characterize a MSC-like 
product coupling an in vitro bioassay interrogating the cellular secretome by enzyme-linked 
immunosorbent assay (ELISA) and a functional cell-based assay. Another industry 
sponsored example is that of Prochymal (Osiris Therapeutics, Inc.), which is an industrial-
scale expanded MSC-like product derived from marrow collected from random donors that 
was studied as part of prospective randomized clinical trials. As a surrogate measure of 
potency, soluble TNFR1 was defined as a release criterion [7]. There are likely other 
potency release assays strategies that have been considered by the Regulatory Authorities 
for MSC-like ATMPs for use in immunomodulation, but these are unpublished and are not 
available for public consultation because Regulatory Authorities are not at liberty to publicly 
disclose otherwise confidential IND disclosure made by Manufacturers (academic or 
industrial). Nonetheless, these precedents inform us that a minimal set of assay components 
to be taken into consideration will likely require direct assay(s) of cell functionalities of 
MSC-like products and possibly a companion cell physiology assay on a responder 
lymphomyeloid cell population.
Functional in vitro assays with responder immune cells
Allogeneic random donor human peripheral blood mononuclear cell (PBMCs) serve as a 
useful tool to decipher MOA of human MSCs. However, there are serious limitations to 
their use as robust and reproducible potency release assay for human clinical trials [8]. 
Activated CD3+ T cells provide the opportunity to measure inhibition of proliferation and 
cytokine production in vitro, yet it is unknown whether this assay accurately reflects the 
MOA of MSCs in vivo. Indeed, there are published pre-clinical data demonstrating that 
MSCs and other stem cell types can influence the cell physiology of monocytes, B-cells, 
natural killer cells and granulocytes, none of which is reflected in a classic mixed 
lymphocyte reaction (MLR)-like assay [9].The use of unfractionated PBMCs collected from 
consenting normal human volunteers contains a mixture of lymphomyeloid cells that varies 
among human subjects and further complicates the reproducibility and interpretation of such 
assays. Finally, if the goal of the immunopotency assay is to highlight the MSC MOA that 
will be effective in a specific clinical setting, the use of purified immune effector cells that 
are involved in the disease pathogenesis rather than unfractionated responder PBMCs could 
be more informative. Considering the inherent shortcomings of using PBMCs in cell 
responder release assays, a reductionist perspective may provide guidance to robust and 
predictive MSC potency assays. One may rationally argue that if the mechanism by which 
MSCs suppress T-cell proliferation in vitro is defined, direct analysis of expression and 
induction of such as outlined earlier by a matrix assay approach may avoid the intrinsic 
variance in using random donor PBMC responder cells as part of descriptive release assay. 
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The key will be defining functionalities that are theoretically causative of suppressor 
function in vivo so as to best inform on comparability of MSC-like platforms and also 
provide guidance on selection of clinical trial subjects which are poised to best respond 
based on hypothesis-driven mechanistic predictors of response.
Assay matrix for MSC-like cells to assay immunomodulation functionalities
The FDA provides guidance on assay systems that can serve as methods to ascertain 
potency/strength of cell therapy such as MSC-like cells. As an aggregate, these assays 
measure specific functionalities that can be correlated with in vitro cell-based systems. From 
a Manufacturer’s perspective (academic or industrial), the assay matrix needs to comply 
with criteria required by the FDA (Table II) and possess certain elements of robustness, 
reproducibility and economy. Taking these in to consideration, workshop participants 
identified three preferred analytic methods that could inform a matrix assay approach: (i) 
quantitative RNA analysis of selected gene products, (ii) flow cytometry analysis of 
functionally relevant surface markers and (iii) protein-based assay of secretome. The 
analysis of MSC-like cells at time of lot release typically is performed on cells that are in log 
phase of growth within the boundaries of manufacturing parameters under study. In essence, 
this is a snapshot of steady-state functionalities. The presence of static cell markers (e.g., 
CD73+, CD90+, CD105+, CD45−) are useful to validate identity of MSC-like products, but 
they have not been demonstrated to act directly or predict for immune modulating function 
[9].Within this context, the use of a “cell ruler” against which released lots are compared 
gains nominal importance [10,11].
Immune plasticity
The MSC committee of the ISCT released a position statement paper in 2013 that proposed 
immunological characterization of Multipotent Mesenchymal Stromal Cells [9]. Relative to 
their homeostatic resting state, MSCs undergo polarization toward inhibitory functionality 
on exposure to various pro-inflammatory cytokines such as interferon (IFN)γ, tumor 
necrosis factor (TNF)-α, IL-1α or IL-1β. In vitro MSC inflammatory “licensing” better 
recapitulates what likely happens in vivo once MSCs are transfused into patients with 
dysregulated immune responses or with systemic inflammation [12]. Measurable 
immunological features of MSCs, both at phenotypic and functional levels, depend on their 
activation status at the time of interaction with effector cells, although variability may be 
observed among different donors [13].Thus, if these functional assays aim to assess the 
immune regulatory functions of MSCs for clinical purposes, comparing the results with both 
resting and licensed MSCs would be most informative, regardless of the tissue origin. 
Different protocols of MSC licensing are available from the literature [14], but normally the 
addition of IFNγ for 12–48 h is adequate to obtain MSC activation that allows for their 
analysis as part of an assay matrix. IFNγ-activated MSC-like cells readily increase 
expression of surface markers relevant to functional immune modulation and are amenable 
to routine clinical flow cytometric analysis (Table III). Similarly, quantitative RNA analysis 
of genes identified in the literature as likely related to MOA (Table IV) before and after 
IFNγ activation MSCs leads to increased transcription of an array of immune relevant genes 
among which a significant subset are increased more than a thousand-fold (e.g., IDO, 
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CXCL9, CXCL10, CXCL11 and CIITA) [15]. Protein-based assays such as ELISA can 
further measure secreted factors produced directly by MSC-like cells, especially those 
amplified by in vitro IFNγ licensing, which can be reasonably postulated to play a role in 
immune modulation. The approach here high-lighted does not exclude the use of alternate 
methods of in vitro MSC licensing such as the use of TLR agonists or distinct cytokines 
(TNF-α, IL-1, etc.), inasmuch as these deploy immune modulation functionalities linked to 
effector function. Further, open-mindedness toward emerging concepts in MSC cell 
physiology and function including, but not restricted to, the influence of exosomes and 
micro RNA, for example, may play a part of release potency assays as their mechanistic role 
becomes better defined.
Controls
As with all well-designed experiments, developing a potency assay must include appropriate 
assay controls and a comparison to an appropriate product-specific reference material, when 
available. Running a product-specific reference material and/or control samples in parallel 
with the product helps ensure that the assay is performing as expected. In addition, controls 
help establish that the equipment and reagents are working within established limits. A well-
designed set of control samples can substantially increase confidence that results are 
meaningful and reliable. The Manufacturer is expected to develop “in-house” reference 
material(s) as part of product development when feasible. These may include well-
characterized clinical lots or other well-characterized materials prepared by the 
Manufacturer or another resource (e.g., a well-characterized cell line with a profile similar to 
MSC-like cells) that has been appropriately qualified. Taking this perspective in 
consideration, the objective of developing a universal MSC “cell ruler” has been addressed 
[16] and in itself represents a challenge almost as great as developing the potency assays for 
which they are to serve as a reference [10]. A complementary approach that may address the 
regulatory requirement for a reference material could include using “resting” MSCs as an 
internal “cell-ruler” control and their contemporaneous “activated” MSCs counterparts as 
the test [12]. In essence, each MSC lot serves as its own “control” when assaying immune 
plasticity.
Perspective statement: A focused analysis of selected markers robustly deployed by in vitro 
cytokine licensing (e.g., IFNγ) of MSCs and metricized with a complementary matrix of 
assays (fluorescence-activated cell sorting, quantitative RNA and proteomic [ELISA]) using 
“resting” MSCs as controls (from the same lot) should be responsive to requirements from 
Regulator Authorities regarding release potency assay (Table II). Candidate MOA 
surrogates outlined in Tables III and IV could serve as potential “universal” markers of 
strength for MSCs developed for their suppressive functionalities. It is also advisable to 
discuss potency development with the Regulatory Authorities early on and before initiation 
of phase 3 trials when potency becomes a Regulatory Authority requirement.
Conclusion
The key deliverable for the translational community invested in developing MSC-like cells 
to their full clinical potential will be defining functionalities which are predictive of their 
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tissue repair and immune and inflammation modulatory functions in vivo to best inform on 
comparability of MSC-like platforms and also provide guidance on selection of clinical trial 
subjects that are poised to best respond based on hypothesis-driven mechanistic predictors of 
response. Although this guidance is focused on release potency assays, these remain tightly 
coupled to companion identity assays that themselves likely require refinement from the 
original 2006 ISCT position paper [1] as new knowledge on MSC-like cells from various 
tissue sources is gained by the field at large. Furthermore, the concept of economy is of 
material importance. Although the cost of release testing of large industrial lots can be easily 
amortized on a per-unit cost, the same is not applicable to one patient/one product setting of 
autologous cell manufacturing or low passage allogeneic MSC doses (usually <10 doses) 
typically manufactured by academic health centers in support of clinical trials. Indeed, 
complex matrix assays using cutting-edge—and expensive—technologies can add 
substantial costs to manufacturing and release of personalized MSC units. Thus, an open 
mind-set by Regulatory Authorities in allowing for use of assays systems that are 
economical, especially in the setting of autologous cell therapies (e.g., one product per 
patient) or for allogeneic products with small number of cell does per lot (as is often done in 
academic health center sponsored allogeneic MSC clinical trials) would be useful. It is also 
desirable that unfettered open access of Regulatory Authority–approved release potency 
assay systems for MSC-like cells by Manufacturers engaged in clinical trials be encouraged 
and embraced by the cell therapy community. Public access of these elements can only be 
achieved by voluntary public disclosure by Manufacturers, and this shared regulatory data 
will further advance the field by allowing stakeholders to adopt rationally developed and 
validated common standards and assays.
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Table I
Challenges to potency assay development for MSC-like products.
Challenges Examples
Inherent variability for starting materials Autologous and allogeneic MSC donor variabiliy
Tissue source for MSCs (adipose, marrow, puerperal products)
Limited lot size and limited material for testing Single-dose therapy using autologous cells suspended in a small volume
Limited stability Viability of cell products
Functionality of cell products at time of administration relative to banking (thawing)
Lack of appropriate reference standards Autologous cell material
Complex MOA Multiple potential effector functions of cells
Multiple steps required for function
In vivo fate of product Migration from site of administration
Half-life of cellular product post administration
Cellular differentiation or activation in to the desired cell type
Adapted from http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/
CellularandGeneTherapy/UCM243392.pdf.
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Table II
Release testing of licensed biological product.
Release testing
Applicable FDA biologics and
cGMP regulations
Indicate potency (biological activity/activities) specific to the product 21 CFR 600.3(s) and 610.10; and 21 CFR 210.3(b)(16)(ii)
Provide quantitative data 21 CFR 211.194; see also 21 CFR 600.3(kk); 21 CFR 211.165(d); 
211.165(e)
Meet pre-defined acceptance and/or rejection criteria 21 CFR 211.165(d); see also 21 CFR 600.3(kk); and 21 CFR 
210.3(b)(20)
Include appropriate reference materials, standards, and/or controls 21 CFR 210.3(b)(16)(ii) and 211.160
Establish and document the accuracy, sensitivity, specificity and 
reproducibility of the test methods used through validation
21 CFR 211.165(e) and 211.194(a)(2))
Measure identity and strength (activity) of all active ingredients 21 CFR 211.165(a); see also 21 CFR 210.3(b)(7))
Provide data to establish dating periods 21 CFR 600.3(l) and 610.53(a)
Meet labeling requirements 21 CFR 610.61(g)(3) and 610.61(r)
Adapted from http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/
CellularandGeneTherapy/UCM243392.pdf.
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Table III
FACS phenotype of resting and IFNγ-primed MSCs.
FACS phenotype Resting IFNγ activated
CD40 − ++
CD80 − −
CD86 − −
HLA-ABC ++ ++++
HLA-DR − +++
CD274 (PD-L1) + ++++
CD54 (ICAM-1) + ++++
Adapted from Krampera et al [9].
FACS, fluorescence-activated cell sorting.
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Table IV
Genes significant to MSC immune-biology amenable to Fluidigm nanoscale qPCR array and/or ELISA.
IDO [13], CXCL10 [17], CXCL9 [18], CXCL11 [19], CIITA [20], ICAM-1 [21], CCL5 [22],TRAIL [23],TLR3 [24], CCL7 [25],VCAM-1 
[21], HLADR [26], HGF [27], IL-6 [28], HLA-G 5 [29], CCL2 [30], PI9 [31], CCR7 [32],VEGF [33], PDL1 [26], CX3CR1 [34], COX-2 [35], 
AHR [36], TSG-6 [37], KGF [38],TLR4 [24], CXCL12 [39], CD46 [40], PDL2 [26],TGF-β [41], CXCR6 [18], CCR10 [42], TIMP-2 [43], 
CD55 [44], BCL-2 [45], ANGPT2 [46], A20 [47], HSP70A [48], IL-8 [24], ULBP-3 [49], HSP70B [48], CXCR1 [50], GAL-1 [51], CXCR4 
[52], HO-1 [53],TIMP-1 [54], IL-1RA [55]
Adapted from Chinnadurai et al [15]. qPCR, quantitative polymerase chain reaction.
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